CORE Shares Myopia, Dry Eye, Contact Lens Comfort, and Foundational Research at BCLA Conference
Wednesday, June 7 2023 | 08 h 15 min | News
A team of researchers and educators from the Centre for Ocular Research & Education (CORE) will present multiple insights this coming week at the 2023 BCLA Clinical Conference. Spanning 11 lectures, paper presentations, and scientific posters, their findings and guidance will include topics such as myopia, dry eye, and contact lens comfort.
The 2023 BCLA Clinical Conference and Exhibition takes place from June 9-11. Nearly 1,000 attendees from around the world are expected to attend.
“CORE’s participation in the BCLA this year exemplifies how we collaborate with sponsors and peers to advance biosciences, clinical research and education—work that is not only intriguing, but has real application with practices and patients,” said Lyndon Jones, FBLCA, CORE’s director.
Myopia management has dominated conference proceedings of late, and it’s the same at this year’s BCLA. CORE Lead Clinical Scientist Debbie Jones, FBCLA, will moderate a panel discussion on managing a myopic patient’s contact lens journey, then present a paper on young adult acceptance of a dual focus soft contact lens.
CORE Head of Clinical Research Jill Woods, FBCLA, joins her to offer a hands-on, 90-minute workshop that will review multifunction instruments for myopia management. Posters on new software for ortho-k fitting success and visual performance of myopia control soft lenses will be presented by CORE Senior Clinical Scientist Doerte Luensmann and CORE Data, Statistics & Website Manager Sarah Guthrie, respectively.
Lyndon Jones is delivering six lectures across all three days, co-presenting with industry sponsors and academic peers on comfort opportunities, clinical myths, presbyopia, and lifestyle impact on the ocular surface. Alongside Professors Jennifer Craig and James Wolffsohn, he will demonstrate the new Dry Eye Wheel, developed in conjunction with the World Council of Optometry.
Dr. Jones will close out BCLA with a discussion of CORE’s fabrication of a microfluidic chip for drug delivery and ocular cytotoxicity evaluation—a breakthrough that attracted substantial attention at the recent ARVO meeting in New Orleans.
